Expertise in
8
conditions

Dr. Emma L. Barber

Oncology
250 E Superior St Ste 4-420, Prentice Women's Hospital, 
Chicago, IL 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Referral may be required
Before you request
Expertise in
8
conditions
250 E Superior St Ste 4-420, Prentice Women's Hospital, 
Chicago, IL 

Overview

Emma Barber is an Oncologist practicing medicine in Chicago, Illinois.

Dr. Barber is highly rated in 8 conditions, according to our data. Her clinical expertise encompasses Endometrial Cancer, Ovarian Cancer, Ovarian Carcinosarcoma, Endoscopy, and Lymphadenectomy.

Dr. Barber is board certified in American Board Of Obstetrics And Gynecology - Gynecologic Oncology (Certified). She is actively involved in clinical research, co-authoring 98 peer reviewed articles and participating in 7 clinical trials. Dr. Barber is currently accepting new patients.

Graduate Institution

Yale University School Of Medicine

Specialties

Oncology

Licenses

Obstetrics & Gynecology in IL

Board Certifications

American Board Of Obstetrics And Gynecology - Gynecologic Oncology (Certified)

Fellowships

University of North Carolina Hospitals
University of North Carolina Hospitals

Hospital Affiliations

Northwestern Memorial Hospital
Northwestern Lake Forest Hospital
Palos Community Hospital
Northwestern Medicine Delnor Community Hospital
Northwestern Medicine Central Dupage Hospital

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 5 Less Insurance Carriers -

Locations

250 E Superior St Ste 4-420, Prentice Women's Hospital, Chicago, IL 60611

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase 1/1b Dose Escalation Study of Abemaciclib and Olaparib for Recurrent Platinum-Resistant Ovarian Cancer
A Phase 1/1b Dose Escalation Study of Abemaciclib and Olaparib for Recurrent Platinum-Resistant Ovarian Cancer
Enrollment Status: Recruiting
Publish Date: August 27, 2026
Intervention Type: Drug, Procedure
Study Drug: Abemaciclib
Study Phase: Phase 1
A Phase III Randomized Trial of Radiation +/- Pembrolizumab (MK-3475) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer
A Phase III Randomized Trial of Radiation +/- Pembrolizumab (MK-3475) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 02, 2026
Intervention Type: Other, Procedure, Radiation, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
Enrollment Status: Active_not_recruiting
Publish Date: March 24, 2026
Intervention Type: Drug, Procedure
Study Drugs: Carboplatin, Letrozole, Paclitaxel
Study Phase: Phase 3
Surgical Window of Opportunity Study of Megestrol Acetate Compared With Megestrol Acetate and Metformin for Endometrial Intraepithelial Neoplasia
Surgical Window of Opportunity Study of Megestrol Acetate Compared With Megestrol Acetate and Metformin for Endometrial Intraepithelial Neoplasia
Enrollment Status: Active_not_recruiting
Publish Date: January 21, 2026
Intervention Type: Other, Procedure, Drug
Study Drugs: Extended Release Metformin Hydrochloride, Megestrol Acetate
Study Phase: Phase 2
A Pilot, Multicenter, Single Arm, Open Label, Surgical Window of Opportunity Study of Abemaciclib and Letrozole for Endometrioid Adenocarcinoma of the Endometrium
A Pilot, Multicenter, Single Arm, Open Label, Surgical Window of Opportunity Study of Abemaciclib and Letrozole for Endometrioid Adenocarcinoma of the Endometrium
Enrollment Status: Completed
Publish Date: October 20, 2025
Intervention Type: Drug, Procedure
Study Drugs: Abemaciclib, Letrozole
Study Phase: Early Phase 1
A Pilot Study of Prehabilitation During the Neoadjuvant Window of Opportunity in Older Women With Ovarian Cancer (FIT4SURGERY)
A Pilot Study of Prehabilitation During the Neoadjuvant Window of Opportunity in Older Women With Ovarian Cancer (FIT4SURGERY)
Enrollment Status: Completed
Publish Date: April 29, 2025
Intervention Type: Behavioral
Study Phase: Not Applicable
An Open Label Phase II Trial of Guadecitabine and Pembrolizumab in Platinum Resistant Recurrent Ovarian Cancer
An Open Label Phase II Trial of Guadecitabine and Pembrolizumab in Platinum Resistant Recurrent Ovarian Cancer
Enrollment Status: Completed
Publish Date: February 20, 2024
Intervention Type: Drug, Other, Biological
Study Drugs: Guadecitabine, Pembrolizumab
Study Phase: Phase 2
View 6 Less Clinical Trials

98 Total Publications

Systemic Treatment of Ovarian Cancer Recurrence: ASCO Living Guideline, Version 2026.1.0.
Systemic Treatment of Ovarian Cancer Recurrence: ASCO Living Guideline, Version 2026.1.0.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 13, 2026
Similar Doctors
Expertise in
25
conditions
Dr. Sonali M. Smith
Hematology | Oncology
Expertise in
25
conditions
Dr. Sonali M. Smith
Hematology | Oncology
Referral may be required

UChicago Medicine River East

355 E. Grand Ave., 
Chicago, IL 
 (0.4 miles away)
888-824-0200
Languages Spoken:
English, Greek, Gujarati , Hindi, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Sonali Smith is a Hematologist and an Oncologist practicing medicine in Chicago, Illinois. Dr. Smith is highly rated in 25 conditions, according to our data. Her clinical expertise encompasses Non-Hodgkin Lymphoma, Follicular Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Smith is board certified in Medical Oncology and Practicing Since2001. Dr. Smith is currently accepting new patients.

Expertise in
17
conditions
Dr. Jessica K. Altman
Hematology | Oncology
Expertise in
17
conditions
Dr. Jessica K. Altman
Hematology | Oncology
Referral may be required
Before you request
675 N St Clair St Ste 21-100, Galter Pavilion, 
Chicago, IL 
 (0.1 miles away)
866-587-4322
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jessica Altman is a Hematologist and an Oncologist practicing medicine in Chicago, Illinois. Dr. Altman is highly rated in 17 conditions, according to our data. Her clinical expertise encompasses Acute Myeloid Leukemia (AML), Leukemia, Acute Promyelocytic Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Altman is board certified in American Board Of Internal Medicine - Hematology (Certified). Dr. Altman is currently accepting new patients.

Expertise in
20
conditions
Expertise in
20
conditions
Referral may be required
Before you request
675 N St Clair St Ste 20-150, Galter Pavilion, 
Chicago, IL 
 (0.1 miles away)
312-695-8146
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Joshua Meeks is an Oncologist practicing medicine in Chicago, Illinois. Dr. Meeks is highly rated in 20 conditions, according to our data. His clinical expertise encompasses Bladder Cancer, Urothelial Cancer, Muscle Invasive Bladder Cancer, Orchiectomy, and Reconstructive Urology Surgery. Dr. Meeks is board certified in American Board Of Urology - Urology (Certified). Dr. Meeks is currently accepting new patients.

Frequently Asked Questions about Dr. Emma L. Barber

How do I make an appointment with Dr. Emma L. Barber?

You can book an appointment with Dr. Emma L. Barber by calling their office at 866-587-4322. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Emma L. Barber a top-rated expert for Endometrial Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Emma L. Barber is classified as an Elite expert for Endometrial Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Emma L. Barber specialize in?

While Dr. Emma L. Barber is a Oncology, they have specific expertise in Endometrial Cancer, Ovarian Cancer, and Ovarian Carcinosarcoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Emma L. Barber participate in research or clinical trials?

Yes. Dr. Emma L. Barber has published 98 articles and abstracts on conditions like Endometrial Cancer. You can view a list of Dr. Emma L. Barber's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Emma L. Barber accept my insurance?

Dr. Emma L. Barber accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 866-587-4322 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Barber's expertise for a condition
ConditionClose
View All 13 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile